A silent surge of drug-resistant fungi already costing lives
In the quiet margins of modern medicine, a crisis has been building in soil and air long before it arrives at the hospital bedside. Fifty researchers from sixteen organizations have published a coordinated warning in Nature Medicine: drug-resistant fungi, shaped partly by agricultural practices, are killing vulnerable patients at rates that demand immediate global attention. Where antibiotic resistance has commanded headlines for decades, fungal resistance has grown in near silence — and for the immunocompromised, that silence can be fatal. The call now is for a coordinated One Health response, uniting agriculture, medicine, and public health before the window for prevention closes further.
- Candida auris is killing one in three patients whose bloodstreams it enters, while resistant Aspergillus is appearing with growing frequency in intensive care units already stretched by other crises.
- The resistance is not born in hospitals — it is cultivated in fields, where agricultural fungicides chemically similar to medical antifungals train environmental fungi to survive, and wind carries those survivors across continents.
- Drug development offers little relief: only five new antifungal drug classes have emerged in seventy-five years, a consequence of fungi's biological closeness to human cells making safe, effective treatments extraordinarily hard to engineer.
- Fifty international researchers have proposed a five-step action plan — awareness, surveillance, infection control, optimized drug use, and new diagnostics — aimed at anchoring updates to the WHO's Global Action Plan on antimicrobial resistance.
- The WHO has acknowledged the gap, but acknowledgment alone has not yet translated into the coordinated global infrastructure needed to track, contain, and counter a threat that remains largely invisible to the public.
Fungi are everywhere — in soil, in air, on skin — and a growing number of them no longer respond to the drugs designed to stop them. For a healthy person, this may mean little. For someone already immunocompromised, it can mean death. That is the warning fifty researchers from sixteen organizations have just delivered in Nature Medicine, a signal they fear is being drowned out by louder alarms about antibiotic-resistant bacteria.
The threats are specific and present. Candida auris kills one in three patients whose bloodstreams it invades. Aspergillus fumigatus, inhaled from the environment, is appearing more frequently in intensive care units. Trichophyton indotineae causes skin infections that resist standard treatment. These are not hypothetical futures — they are unfolding now, in hospitals across the world.
What makes the crisis hard to see is where it begins: not in wards, but in fields. Agricultural fungicides, chemically similar to the antifungal drugs used in medicine, expose soil fungi to selection pressure year after year. Resistant strains develop, travel through air, and arrive at hospital bedsides already immune to the treatments waiting for them. It is, at its core, a One Health problem — one that agriculture, medicine, and public health must confront together.
The path forward is further complicated by the biology of fungi themselves. Their cellular structure resembles human cells far more than bacteria do, making it difficult to develop drugs that kill the pathogen without harming the patient. Only five new antifungal drug classes have been developed in seventy-five years. There is no surge of new treatments on the horizon. Prevention, the researchers argue, is not merely preferable — it is the only realistic strategy.
Their five-step proposal — building awareness, establishing surveillance, strengthening hospital infection controls, optimizing existing drug use, and investing in new diagnostics — is being offered as a framework for the WHO's forthcoming update to its Global Action Plan on antimicrobial resistance. The WHO has signaled openness to expanding its focus on fungal infections specifically. Whether that openness translates into the coordinated global action the moment requires remains the defining question.
Fungi are everywhere—in soil, in air, on skin—and an increasing number of them no longer respond to the drugs designed to kill them. For a healthy person, this might mean nothing at all. For someone whose immune system is already compromised, it can mean death. This is the warning that fifty researchers from sixteen organizations across the globe have just published in Nature Medicine, and it carries an urgency that has so far been drowned out by louder alarms about antibiotic-resistant bacteria.
The threat is real and specific. Candida auris, a fungus that can invade the bloodstream in hospital patients, kills one in three people it infects. Aspergillus fumigatus, which we breathe in from the environment, can devastate the lungs—and hospitals have been seeing it more frequently in recent years, particularly in intensive care units where patients are already fighting influenza or other serious illnesses. A newer threat, Trichophyton indotineae, causes severe skin infections that resist standard treatment. These are not theoretical problems. They are happening now, in hospitals and communities around the world.
What makes this crisis particularly difficult to see is that it originates not in hospitals but in fields. Farmers use fungicides to protect crops from fungal diseases, and these agricultural chemicals are chemically similar to the antifungal drugs that doctors use to treat human infections. When fungi in soil are exposed to these fungicides year after year, they develop resistance. Those resistant fungi then travel through the air, spreading across regions and continents. By the time they reach a hospital patient, the drugs that should save their life no longer work. The problem, in other words, is not confined to medicine—it is a One Health problem, one that requires agriculture, medicine, and public health to act in concert.
Paul Verweij, a medical microbiologist at Radboudumc in the Netherlands who led the research effort, points to a structural challenge that makes the situation worse: developing new antifungal drugs is extraordinarily difficult. The cell structure of fungi is far more similar to human cells than bacterial cells are. This means that any drug potent enough to kill fungi risks damaging human tissue as well. In the past seventy-five years, only five new classes of antifungal drugs have been developed. Compare that to the dozens of new antibiotics created in the same period, and the gap becomes clear. There is no cavalry coming. Prevention is not just preferable—it is essential.
The researchers have proposed a five-step plan: build awareness of the problem, establish surveillance systems to track resistance, strengthen infection prevention and control measures in hospitals, optimize the use of existing antifungal drugs to slow resistance, and invest in new diagnostics and treatments. The plan is being positioned as a foundation for updates to the World Health Organization's Global Action Plan on antimicrobial resistance, which is scheduled for revision later this year. Haileyesus Getahun, who directs the WHO's program on antimicrobial resistance, has acknowledged the need: more data, more evidence, more attention to fungal infections specifically.
What is striking about this moment is how quietly it is arriving. Antibiotic resistance has dominated headlines for years. Fungal resistance, by contrast, remains largely invisible—a silent surge, as Verweij describes it. The patients most at risk are those already vulnerable: people with weakened immune systems, those in intensive care, the elderly. For them, a fungal infection that does not respond to treatment is not an inconvenience. It is a death sentence. The researchers are calling for action now, before resistance spreads further, before more patients die from infections that medicine can no longer treat. Whether the world listens remains to be seen.
Citas Notables
We are facing a silent surge of drug-resistant fungi—from Candida auris in ICUs to azole-resistant Aspergillus in the community—that is already costing lives.— Paul E. Verweij, Professor, Radboud University Medical Center
Dual use of antifungal targets in medicine and agriculture is accelerating resistance from fields to ICUs. Aligning agricultural authorizations with health risk assessments is a pragmatic One Health solution.— Professor Michaela Lackner, Medical University of Innsbruck
La Conversación del Hearth Otra perspectiva de la historia
Why has fungal resistance gotten so little attention compared to antibiotic resistance?
Because fungi are everywhere and usually harmless to healthy people. A resistant bacterium is obviously dangerous. A resistant fungus in soil seems irrelevant until it reaches someone in an ICU.
But the source of the resistance is agriculture, not hospitals. How does that work?
Farmers spray fungicides on crops that are chemically similar to the drugs doctors use. Fungi in the soil adapt to survive those sprays. Once they're resistant, they spread through the air. The resistance is born in the field and travels to the hospital.
So this is a One Health problem—you can't solve it by just changing hospital practices.
Exactly. You could sterilize every hospital in the world and still lose patients to resistant fungi blowing in from agricultural regions. You need farmers, doctors, and public health officials all working from the same playbook.
Why is developing new antifungal drugs so hard?
Fungi are too much like us. Their cells are similar enough to human cells that a drug strong enough to kill them often damages us too. Bacteria are different enough that you can target them without harming the patient. With fungi, you're always walking a knife's edge.
Only five new antifungal drug classes in seventy-five years. That's striking.
It is. And it means we can't rely on innovation to save us. We have to make the drugs we have last as long as possible, which means preventing resistance from developing in the first place.
What happens to a patient who gets infected with a resistant fungus?
If it's Candida auris in the bloodstream, one in three patients dies. If it's Aspergillus in the lungs, you're looking at severe damage that may not be reversible. These aren't mild infections. These are the kind that end lives.